Clinical Developments in Follicular Lymphoma

Follicular lymphoma (FL) is a rare, slow-growing type of blood cancer. People living with this form of non-Hodgkin lymphoma often experience multiple relapses over many years—sometimes even decades—as there is currently no cure. For a small subset of patients, the disease progresses much more rapidly, with five-year survival rates dropping to around 50 percent.

In collaboration with the Follicular Lymphoma Foundation (FLF), SPARC conducted a comprehensive analysis of the FL landscape. This report examines the current and emerging therapeutic advances in FL, showcases FLF’s leadership in advancing research, and outlines the most promising routes toward a cure. While drug development for FL has expanded significantly over the past five years, the findings underscore several critical gaps that must be addressed to accelerate progress toward lasting treatments and, ultimately, a cure.